As we have turned the leaf to 2023, I figured I’d share the publications I had last year:
- Forma F, Chiu K, Shafrin J, Boskovic DH, Veeranki SP. Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness. Digital health. 2022 Mar;8:20552076221084472.
- Jackisch C, Manevy F, Frank S, Roberts N, Shafrin J. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example. Advances in Therapy. 2022 Feb;39(2):833-44.
- Maksabedian Hernandez EJ, Graf M, Portelli A, Shafrin J. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. Journal of Medical Economics. 2022 Dec 31;25(1):1118-26.
- Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, Pedro S, Kim N, Yi E, Michaud K. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. Journal of managed care & specialty pharmacy. 2022 Sep;28(9):1008-20.
- Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, Pedro S, Hass S, Hur P, Kim N, Yi E. Health care utilization and costs associated with functional status in patients with psoriatic arthritis. Journal of managed care & specialty pharmacy. 2022 Sep;28(9):997-1007.
- Shafrin J, Marijam A, Joshi AV, Mitrani-Gold FS, Everson K, Tuly R, Rosenquist P, Gillam M, Ruiz ME. Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records. Antimicrobial Resistance & Infection Control. 2022 Dec;11(1):1-3.
- Shafrin J, Marijam A, Joshi AV, Mitrani-Gold FS, Everson K, Tuly R, Rosenquist P, Gillam M, Ruiz ME. Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database. Antimicrobial Resistance & Infection Control. 2022 Dec;11(1):1-3.
- Waheed A, Clayton D, Shafrin J, Li F, Shi Y, Geevarghese L, Yen GP. Cost to Treat Newly Diagnosed Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis. Blood. 2022 Nov 15;140(Supplement 1):5033-4.
- Shafrin J, Mubayi A, Birch K, Land N, Sotak M, Venkatachalam M, Theriou C, Ayad M. Economic Impact of Sequential Testing for COVID-19 and Influenza with Molecular Point of Care in 3 European Countries. Value in Health. 2022 Jul 1;25(7):S426.
- FTI Consulting. The role of intellectual property in the biopharmaceutical sector. September 21, 2022.